Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19602434 | 0.84 | SMN1; SMN2 (0.76) | USP2POLBALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL12646347 | 0.81 | USP2 (0.68) | USP2POLBALDH1A1GAATDP1 | |
| SCHEMBL3341489 | 0.81 | USP2 (0.68) | USP2POLBALDH1A1MAPTNPC1 | |
| SCHEMBL6302757 | 0.81 | USP2 (0.68) | USP2POLBALDH1A1MAPTNPC1 | |
| SCHEMBL2517123 | 0.81 | MEN1 (0.62) | USP2ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL28254939 | 0.81 | USP2 (0.67) | USP2POLBALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12189227 | 0.80 | USP2 (0.71) | USP2ALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL5018987 | 0.80 | USP2 (0.71) | USP2POLBALDH1A1SMN1; SMN2GAA | |
| SCHEMBL5018821 | 0.80 | USP2 (0.71) | USP2POLBALDH1A1SMN1; SMN2GAA | |
| SCHEMBL3000302 | 0.80 | USP2 (0.59) | USP2POLBALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825160-B2 | such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity | CELLZOME LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | CELLZOME AG (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1805129-B1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1805129-A1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME AG (DE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006045554-A1 | (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | CELLZOME AG (DE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118289-A1 | (Biphenyl) Carboxylic Acids and Derivatives Thereof | BACE1, BACE2, APP | USP2 2280/4885POLB 1979/4885ALDH1A1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.